04 Jul, EOD - Indian

Nifty Bank 57031.9 (0.42)

Nifty Midcap 100 59677.75 (-0.01)

Nifty Next 50 68607.8 (0.37)

Nifty 50 25461 (0.22)

Nifty IT 39166.55 (0.80)

Nifty Smallcap 100 19033.05 (0.03)

Nifty Pharma 22384.6 (0.81)

SENSEX 83432.89 (0.23)

04 Jul, EOD - Global

NIKKEI 225 39810.88 (0.06)

HANG SENG 23916.06 (-0.64)

S&P 6295.5 (-0.64)

LOGIN HERE

flagBajaj Healthcare Ltd

You are Here : Home > Markets > CompanyInformation > Company Background
BSE Code : 539872 | NSE Symbol : BAJAJHCARE | ISIN : INE411U01027 | Industry : Pharmaceuticals |


Company History

Incorporated in 1993, Maharashtra-based Bajaj Healthcare Limited is one of India's large scale and vertically integrated pharmaceutical manufacturer for quality-conscious customers. The Company is engaged in the manufacturing of Active Pharmaceutical Ingredient (APIs), Intermediates, Finished Dosage Forms & Nutraceuticals.

The Company commenced its operations in 1993 with a single unit at Tarapur. It became a public company in 2005 and listed its shares in the Indian stock exchanges in 2016.

With Headquartered in Thane, Company has established 3 API plants in Gujarat and Maharashtra. It has 4 units for APIs/ intermediates and one unit for formulation, which are designed to meet the requirements of both advanced as well as emerging market opportunities. In 2008, the Company acquired Formulations plant at Manjusar, Vadodara and have converted it into WHO-GMP compliant facility. In 2013, it set up another API and Intermediate manufacturing plant at Panoli, Ankleshwar and acquired and set up an Intermediate Unit in Tarapur MIDC, near Mumbai in November, 2014.

In FY 2019-20, the Company acquired Intermediates manufacturing Unit at MIDC, Tarapur Maharashtra and also agreed to acquire Four Manufacturing facilities, comprising of three APIs manufacturing facilities, one Engineering Unit, at MIDC Tarapur, Maharashtra along with an Industrial Plot at Dahej, Gujarat.

The Company started commercial operations at Panoli Unit, in Bharuch from May 11, 2022. In 2021-22, it launched a Nutraceutical named Magnesium L-Threonate; commenced commercial production at Tarapur, for Nimesulide API, used for relief from pain and prevention of fever.

In 2023, the Company further launched 9 new molecules such as Glycine, Piperaquine phosphate, Amodiaquine hydrochloride, 4-7 DCQ, Hydroxy Novaldamine, 6-Chlorohexanone, Lafutidine, Zinc Ascorbate, Rivaroxaban in the Nutraceuticals, APIs, and Formulations segments.

In FY 2024, Company expanded the operations in the Alkaloids manufacturing business. It also established a new facility with the capacity to process approximately 250 metric tons of opium gum and around 2,500 metric tons of poppy straw.

Capital Market Publishers India Pvt. Ltd

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071, India.

Formed in 1986, Capital Market Publishers India Pvt Ltd pioneered corporate databases and stock market magazine in India. Today Capitaline corporate database cover more than 35,000 listed and unlisted Indian companies. Latest technologies and standards are constantly being adopted to keep the database user-friendly, comprehensive and up-to-date.

Over the years the scope of the databases has enlarged to cover economy, sectors, mutual funds, commodities and news. Many innovative online and offline applications of these databases have been developed to meet various common as well as customized requirements.

While all the leading institutional investors use Capitaline databases, Capital Market magazine gives access to the databases to individual investors through Corporate Scoreboard. Besides stock market and company-related articles, the magazine’s independent and insightful coverage includes mutual funds, taxation, commodities and personal finance.

Copyright @ Capital Market Publishers India Pvt.Ltd

Designed, Developed and maintained by CMOTS Infotech (ISO 9001:2015 Certified)

Site best viewed in Internet Explorer Edge ,   Google Chrome 115.0.5790.111 + ,   Mozilla Firefox 115.0.3 + ,   Opera 30.0+, Safari 16.4.1 +